表紙
市場調査レポート

ADC Therapeutics Sarl の製品パイプライン分析

ADC Therapeutics Sarl - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 318950
出版日 ページ情報 英文 26 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
ADC Therapeutics Sarl の製品パイプライン分析 ADC Therapeutics Sarl - Product Pipeline Review - 2015
出版日: 2015年02月24日 ページ情報: 英文 26 Pages
概要

ADC Therapeutics Sarl はスイスに本社を持つ創薬企業です。乳癌、前立腺癌、腎がん、血液がんといった主要な癌を標的としたADCの開発に注力しています。Spirogen Limited、Cancer Research Technologyとの戦略的提携により研究開発を進めています。

当レポートでは、ADC Therapeutics Sarl における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

ADC Therapeutics Sarl の基本情報

  • ADC Therapeutics Sarl の概要
  • 主要情報
  • 企業情報

ADC Therapeutics Sarl :R&Dの概要

  • 主な治療範囲

ADC Therapeutics Sarl :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

ADC Therapeutics Sarl :パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

ADC Therapeutics Sarl :薬剤プロファイル

  • ADCT-401
  • Monoclonal Antibody Conjugates for Prostate Cancer
  • Monoclonal Antibody Conjugates for Solid Tumor and Blood Cancer
  • VM-101
  • Monoclonal Antibody Conjugates for Cancer

ADC Therapeutics Sarl :パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

ADC Therapeutics Sarl :最新のパイプライン情報

ADC Therapeutics Sarl :開発休止中のプロジェクト

ADC Therapeutics Sarl :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06797CDB

Summary

Global Markets Direct's, 'ADC Therapeutics Sarl - Product Pipeline Review - 2015', provides an overview of the ADC Therapeutics Sarl's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ADC Therapeutics Sarl's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ADC Therapeutics Sarl including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ADC Therapeutics Sarl's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ADC Therapeutics Sarl's pipeline products

Reasons to buy

  • Evaluate ADC Therapeutics Sarl's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ADC Therapeutics Sarl in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ADC Therapeutics Sarl's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ADC Therapeutics Sarl and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ADC Therapeutics Sarl
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ADC Therapeutics Sarl and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ADC Therapeutics Sarl Snapshot
    • ADC Therapeutics Sarl Overview
    • Key Information
    • Key Facts
  • ADC Therapeutics Sarl - Research and Development Overview
    • Key Therapeutic Areas
  • ADC Therapeutics Sarl - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • ADC Therapeutics Sarl - Pipeline Products Glance
    • ADC Therapeutics Sarl - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ADC Therapeutics Sarl - Drug Profiles
    • ADCT-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADCT-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Solid Tumor and Blood Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ADC Therapeutics Sarl - Pipeline Analysis
    • ADC Therapeutics Sarl - Pipeline Products by Target
    • ADC Therapeutics Sarl - Pipeline Products by Molecule Type
    • ADC Therapeutics Sarl - Pipeline Products by Mechanism of Action
    • ADC Therapeutics Sarl - Recent Pipeline Updates
  • ADC Therapeutics Sarl - Dormant Projects
  • ADC Therapeutics Sarl - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ADC Therapeutics Sarl, Key Information
  • ADC Therapeutics Sarl, Key Facts
  • ADC Therapeutics Sarl - Pipeline by Indication, 2015
  • ADC Therapeutics Sarl - Pipeline by Stage of Development, 2015
  • ADC Therapeutics Sarl - Monotherapy Products in Pipeline, 2015
  • ADC Therapeutics Sarl - Partnered Products in Pipeline, 2015
  • ADC Therapeutics Sarl - Partnered Products/ Combination Treatment Modalities, 2015
  • ADC Therapeutics Sarl - Preclinical, 2015
  • ADC Therapeutics Sarl - Discovery, 2015
  • ADC Therapeutics Sarl - Pipeline by Target, 2015
  • ADC Therapeutics Sarl - Pipeline by Molecule Type, 2015
  • ADC Therapeutics Sarl - Pipeline Products by Mechanism of Action, 2015
  • ADC Therapeutics Sarl - Recent Pipeline Updates, 2015
  • ADC Therapeutics Sarl - Dormant Developmental Projects,2015

List of Figures

  • ADC Therapeutics Sarl - Pipeline by Top 10 Indication, 2015
  • ADC Therapeutics Sarl - Pipeline by Stage of Development, 2015
  • ADC Therapeutics Sarl - Monotherapy Products in Pipeline, 2015
  • ADC Therapeutics Sarl - Pipeline by Top 10 Molecule Type, 2015
Back to Top